Back

The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction

Cardiovascular Research

18 December 2019
Organised by: Logo
Read full article
ESC Journals

Contributors

Subodh Verma
Subodh Verma

Author

St. Michael's Hospital Toronto , Canada

You may be interested in
thumbnail
Congress Session
Pioneering advances in HFrEF management: unlocking the potential of sGC stimulation
18 May 2025
thumbnail
Congress Presentation
Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
29 June 2021
thumbnail
Congress Presentation
Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)
31 August 2024
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources